Laurion Capital Management LP purchased a new stake in shares of Anavex Life Sciences Corp (NASDAQ:AVXL) in the second quarter, HoldingsChannel.com reports. The institutional investor purchased 51,224 shares of the biotechnology company’s stock, valued at approximately $134,000.

Other institutional investors and hedge funds have also modified their holdings of the company. PHH Investments Ltd. boosted its position in shares of Anavex Life Sciences by 169.6% during the 2nd quarter. PHH Investments Ltd. now owns 39,900 shares of the biotechnology company’s stock valued at $105,000 after acquiring an additional 25,100 shares during the last quarter. Millennium Management LLC boosted its position in shares of Anavex Life Sciences by 95.2% during the 4th quarter. Millennium Management LLC now owns 44,895 shares of the biotechnology company’s stock valued at $145,000 after acquiring an additional 21,895 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of Anavex Life Sciences by 48.8% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 76,200 shares of the biotechnology company’s stock valued at $211,000 after acquiring an additional 25,000 shares during the last quarter. LMR Partners LLP bought a new stake in shares of Anavex Life Sciences during the 2nd quarter valued at about $319,000. Finally, Northern Trust Corp boosted its position in shares of Anavex Life Sciences by 6.3% during the 1st quarter. Northern Trust Corp now owns 449,761 shares of the biotechnology company’s stock valued at $1,241,000 after acquiring an additional 26,595 shares during the last quarter. Hedge funds and other institutional investors own 20.01% of the company’s stock.

AVXL has been the subject of a number of research analyst reports. HC Wainwright initiated coverage on Anavex Life Sciences in a research report on Wednesday, May 30th. They set a “buy” rating and a $10.00 price target for the company. Maxim Group reiterated a “buy” rating and set a $7.00 price target on shares of Anavex Life Sciences in a research report on Thursday, August 9th. Finally, Zacks Investment Research upgraded Anavex Life Sciences from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research report on Tuesday, August 14th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Anavex Life Sciences has an average rating of “Buy” and a consensus price target of $6.60.

NASDAQ:AVXL opened at $2.49 on Monday. Anavex Life Sciences Corp has a 1-year low of $1.85 and a 1-year high of $5.15.

Anavex Life Sciences (NASDAQ:AVXL) last released its earnings results on Thursday, August 9th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.04. analysts anticipate that Anavex Life Sciences Corp will post -0.42 EPS for the current fiscal year.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers. The company's lead drug candidates include ANAVEX 2-73, which has completed Phase IIa clinical trials for the treatment of Alzheimer's disease; and in preclinical clinical trials to treat Parkinson's disease, epilepsy, Rett syndrome, Angelman syndrome, multiple sclerosis, and Fragile X syndrome.

Recommended Story: Is the Dow Jones Industrial Average (DJIA) still relevant?

Want to see what other hedge funds are holding AVXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anavex Life Sciences Corp (NASDAQ:AVXL).

Institutional Ownership by Quarter for Anavex Life Sciences (NASDAQ:AVXL)

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.